230 related articles for article (PubMed ID: 30422005)
1. Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer.
Batra A; Winquist E
Expert Opin Emerg Drugs; 2018 Dec; 23(4):271-282. PubMed ID: 30422005
[TBL] [Abstract][Full Text] [Related]
2. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
3. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer.
Seisen T; Rouprêt M; Gomez F; Malouf GG; Shariat SF; Peyronnet B; Spano JP; Cancel-Tassin G; Cussenot O
Cancer Treat Rev; 2016 Jul; 48():25-33. PubMed ID: 27327958
[TBL] [Abstract][Full Text] [Related]
5. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.
Stice JP; Wardell SE; Norris JD; Yllanes AP; Alley HM; Haney VO; White HS; Safi R; Winter PS; Cocce KJ; Kishton RJ; Lawrence SA; Strum JC; McDonnell DP
Mol Cancer Res; 2017 Jun; 15(6):660-669. PubMed ID: 28209757
[TBL] [Abstract][Full Text] [Related]
7. Progress in the mechanism and drug development of castration-resistant prostate cancer.
Zuo M; Xu X; Li T; Ge R; Li Z
Future Med Chem; 2016 May; 8(7):765-88. PubMed ID: 27149562
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
9. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
Fujimoto N
J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate for the treatment of prostate cancer.
Ryan CJ; Cheng ML
Expert Opin Pharmacother; 2013 Jan; 14(1):91-6. PubMed ID: 23199349
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer.
Han CS; Patel R; Kim IY
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):967-75. PubMed ID: 25936418
[TBL] [Abstract][Full Text] [Related]
12. Advancing therapies in metastatic castration-resistant prostate cancer.
Baciarello G; Gizzi M; Fizazi K
Expert Opin Pharmacother; 2018 Nov; 19(16):1797-1804. PubMed ID: 30311804
[TBL] [Abstract][Full Text] [Related]
13. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].
Basset V; Flamand V; Crouzet S; Ploussard G
Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738
[TBL] [Abstract][Full Text] [Related]
14. Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.
Recine F; Ceresoli GL; Baciarello G; Cerbone L; Calabrò F
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):400-10. PubMed ID: 26337241
[TBL] [Abstract][Full Text] [Related]
15. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M
Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
[TBL] [Abstract][Full Text] [Related]
16. Sequencing of agents for castration-resistant prostate cancer.
Hurwitz M; Petrylak DP
Oncology (Williston Park); 2013 Nov; 27(11):1144-9, 1154-8. PubMed ID: 24575543
[TBL] [Abstract][Full Text] [Related]
17. Emerging agents for the therapy of advanced prostate cancer.
Hathaway AR; Baker MK; Sonpavde G
Future Oncol; 2015; 11(20):2775-87. PubMed ID: 26367474
[TBL] [Abstract][Full Text] [Related]
18. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
[TBL] [Abstract][Full Text] [Related]
19. Molecular alterations and emerging targets in castration resistant prostate cancer.
Lorente D; De Bono JS
Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
[TBL] [Abstract][Full Text] [Related]
20. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]